Plus Roche's annual framing of their drug-price approach
And a ridiculous argument that making pro-innovation claims is 'bullying'
And the insulin price-cap debate remains mired in the congressional mud
And STAT's attempt to survey pharma about IRA highlights a huge catch-22 for industry
Plus an effort to dismantle -- or at least rethink -- today's high-profile NYT op-ed
Plus some thinking about reputation, and lots and lots of other news
And an answer on the Stelera IRA-list mystery
Plus: I put ChatGPT on the obesity beat
Including one correction, of sorts, an op-ed worth reading, and deets on the CMS listening sessions
So here are my first dozen thoughts
And the AZ suit to derail the IRA zigs when others zag
And an updated version of my IRA lawsuit tracker
